NYSE:BLCO

Bausch + Lomb (BLCO) Stock Price, News & Analysis

$15.10
+0.20 (+1.34%)
(As of 08:00 AM ET)
Today's Range
$15.10
$15.10
50-Day Range
$14.06
$17.60
52-Week Range
$13.62
$21.95
Volume
100 shs
Average Volume
471,288 shs
Market Capitalization
$5.31 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$19.50

Bausch + Lomb MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
30.9% Upside
$19.50 Price Target
Short Interest
Healthy
3.92% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.33mentions of Bausch + Lomb in the last 14 days
Based on 7 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
35.38%
From $0.65 to $0.88 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.37 out of 5 stars

Medical Sector

267th out of 907 stocks

Ophthalmic Goods Industry

3rd out of 7 stocks

BLCO stock logo

About Bausch + Lomb Stock (NYSE:BLCO)

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. Its Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation is a subsidiary of Bausch Health Companies Inc.

BLCO Stock Price History

BLCO Stock News Headlines

top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)
AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.
Bausch + Lomb (NYSE:BLCO) Price Target Cut to $18.00
Bausch + Lomb Corporation (BLCO)
top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)
AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.
BLCO Crosses Above Key Moving Average Level
BLCO Apr 2024 17.500 call
BHC Feb 2024 10.000 put
Bausch + Lomb price target raised by $2 at Wells Fargo, here's why
Q4 2023 Bausch + Lomb Corp Earnings Call
Needham Reaffirms Their Hold Rating on Bausch + Lomb Corporation (BLCO)
See More Headlines
Receive BLCO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bausch + Lomb and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/21/2024
Today
4/25/2024
Next Earnings (Confirmed)
5/01/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Ophthalmic goods
Sub-Industry
N/A
Fax
N/A
Employees
13,300
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$19.50
High Stock Price Target
$25.00
Low Stock Price Target
$16.00
Potential Upside/Downside
+30.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
10 Analysts

Profitability

Net Income
$-260,000,000.00
Pretax Margin
-4.00%

Debt

Sales & Book Value

Annual Sales
$4.15 billion
Cash Flow
$1.94 per share
Book Value
$19.72 per share

Miscellaneous

Free Float
N/A
Market Cap
$5.24 billion
Optionable
Optionable
Beta
0.36
The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Mr. Osama A. Eldessouky (Age 52)
    Executive VP & CFO
    Comp: $1.09M
  • Dr. Yehia Hashad M.D. (Age 57)
    Executive VP of Research & Development and Chief Medical officer
    Comp: $1.09M
  • Mr. Brenton L. Saunders J.D. (Age 54)
    CEO & Chairman
  • Mr. Alan Waterhouse CPFA (Age 64)
    MBA, Executive VP and Chief Supply Chain & Operations Officer
  • Mr. Frederick J. Munsch (Age 53)
    Senior VP, Controller & Chief Accounting Officer
  • Mr. A. Robert D. Bailey (Age 61)
    Executive VP & Chief Legal Officer
  • Mr. Jonathon L. Kellerman
    Chief Compliance Officer
  • T.J. Crawford
    Chief Communications Officer
  • Dr. Manisha A. Narasimhan Ph.D. (Age 47)
    Chief Corporate Development & Digital Officer
  • Ms. Asli Gevgilili
    Executive VP & Chief Human Resources Officer

BLCO Stock Analysis - Frequently Asked Questions

Should I buy or sell Bausch + Lomb stock right now?

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Bausch + Lomb in the last year. There are currently 5 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" BLCO shares.
View BLCO analyst ratings
or view top-rated stocks.

What is Bausch + Lomb's stock price target for 2024?

10 analysts have issued 12-month price targets for Bausch + Lomb's shares. Their BLCO share price targets range from $16.00 to $25.00. On average, they predict the company's share price to reach $19.50 in the next twelve months. This suggests a possible upside of 30.9% from the stock's current price.
View analysts price targets for BLCO
or view top-rated stocks among Wall Street analysts.

How have BLCO shares performed in 2024?

Bausch + Lomb's stock was trading at $17.06 at the beginning of the year. Since then, BLCO stock has decreased by 12.7% and is now trading at $14.90.
View the best growth stocks for 2024 here
.

Are investors shorting Bausch + Lomb?

Bausch + Lomb saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 1,500,000 shares, an increase of 22.0% from the March 15th total of 1,230,000 shares. Based on an average trading volume of 436,800 shares, the short-interest ratio is currently 3.4 days. Currently, 3.9% of the shares of the stock are sold short.
View Bausch + Lomb's Short Interest
.

When is Bausch + Lomb's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our BLCO earnings forecast
.

How can I listen to Bausch + Lomb's earnings call?

Bausch + Lomb will be holding an earnings conference call on Wednesday, May 1st at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 919-882-2331 with passcode "49631".

How were Bausch + Lomb's earnings last quarter?

Bausch + Lomb Co. (NYSE:BLCO) issued its quarterly earnings data on Wednesday, February, 21st. The company reported $0.24 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.17 by $0.07. The company had revenue of $1.17 billion for the quarter, compared to analysts' expectations of $1.11 billion. Bausch + Lomb had a negative net margin of 6.27% and a positive trailing twelve-month return on equity of 3.70%. The firm's quarterly revenue was up 17.8% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.23 EPS.

What ETF holds Bausch + Lomb's stock?

Ballast Small/Mid Cap ETF holds 158,240 shares of BLCO stock, representing 1.85% of its portfolio.

What guidance has Bausch + Lomb issued on next quarter's earnings?

Bausch + Lomb issued an update on its FY 2024 earnings guidance on Wednesday, February, 21st. The company provided EPS guidance of for the period. The company issued revenue guidance of $4.6 billion-$4.7 billion, compared to the consensus revenue estimate of $6.1 billion.

When did Bausch + Lomb IPO?

Bausch + Lomb (BLCO) raised $788 million in an IPO on Friday, May 6th 2022. The company issued 35,000,000 shares at $21.00-$24.00 per share.

Who are Bausch + Lomb's major shareholders?

Bausch + Lomb's stock is owned by a variety of institutional and retail investors. Top institutional investors include Renaissance Capital LLC (0.01%).

How do I buy shares of Bausch + Lomb?

Shares of BLCO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:BLCO) was last updated on 4/25/2024 by MarketBeat.com Staff

From Our Partners